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Abstract
Background: Resveratrol, a constituent of red wine, is important for cardioprotection. MicroRNAs are known regulators for
genes involved in resveratrol-mediated cardiac remodeling and the regulatory pathway involving microRNA has not been
studied so far.
Methods: We explored the cardioprotection by resveratrol in ischemia/reperfusion model of rat and determined cardiac
functions. miRNA profile was determined from isolated RNA using quantitative Real-time PCR based array. Systemic analyses
of miRNA array and theirs targets were determined using a number of computational approaches.
Results: Cardioprotection by resveratrol and its derivative in ischemia/reperfusion [I/R] rat model was examined with miRNA
expression profile. Unique expression pattern were found for each sample, particularly with resveratrol [pure compound]
and longevinex [commercial resveratrol formulation] pretreated hearts. Longevinex and resveratrol pretreatment modulates
the expression pattern of miRNAs close to the control level based on PCA analyses. Differential expression was observed in
over 25 miRNAs, some of them, such as miR-21 were previously implicated in cardiac remodeling. The target genes for the
differentially expressed miRNA include genes of various molecular function such as metal ion binding, sodium-potassium
ion, transcription factors, which may play key role in reducing I/R injury.
Conclusion: Rats pretreated with resveratrol for 3 weeks leads to significant cardioprotection against ischemia/reperfusion
injury. A unique signature of miRNA profile is observed in control heart pretreated with resveratrol or longevinex. We have
determined specific group of miRNA in heart that have altered during IR injuries. Most of those altered microRNA
expressions modulated close to their basal level in resveratrol or longevinex treated I/R mice.
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Introduction
Resveratrol is a naturally occurring phytoalexin belonging to
stilbene family of compounds and its IUPAC (International Union
of Pure and Applied Chemistry) nomenclature is 3,49,5-trihydrox-
ystilbene. The most commonly found trans isomer of resveratrol
possesses greater biological activity due to the presence of the 49-
hydroxystyryl group. Although resveratrol was first found as an
anti-proliferative agent for cancer [1], overwhelming epidemio-
logical and experimental evidence documents resveratrol as a
cardioprotective agent, which supports the concept of red wine for
maintaining a healthy heart [2]. It is increasingly clear that
resveratrol is beneficial against diverse cardiac diseases including
ischemic heart disease, hypertrophy, heart failure, atherosclerosis,
hypertension, diabetes and obesity [3,4]. In addition to being
cardioprotective, resveratrol has been found to be beneficial
against a variety of degenerative diseases including lung disease,
alzheimer disease, hepatotoxicity, radiation damage, herpes virus
[4,5]. Resveratrol also have protective role in endothelial cells by
modulating mitochondrial oxidative stress [6].
Initially, resveratrol was believed to function as an antioxidant.
However resveratrol is a poor antioxidant in vitro, but in vivo
resveratrol functions as a potent antioxidant presumably through
its ability to up-regulate nitric oxide [7]. The most prominent
mechanism of action is probably through its ability to perform
intracellular signaling and altering gene expression. Resveratrol
can alter a variety of genes thereby changing the ‘‘death signal’’
into a ‘‘survival signal’’ [8]. The most prominent mechanism
appears its ability to induce several longevity genes including Sirt1,
Sirt3, Sirt4, FoxO1, Foxo3a and PBEF [4]. Thus resveratrol prevents
aging-related decline in cardiovascular function including choles-
terol level and inflammatory response without affecting actual
survival or life span of mice [4].
Since the cardioprotective abilities of resveratrol are intimately
linked to the regulation of genes, it appears to be important to
understand how resveratrol-mediated cardiac gene expression is
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transcription factors are associated with their regulatory DNA
elements. The discovery of miRNAs has enhanced our under-
standing of gene expression at the post-transcriptional level.
MicroRNAs are endogeneous small RNAs (less than 25 nt) that
play key regulatory roles targeting mRNA for specific cleavage,
mRNA deadenylation and decay, translational repression or
activation [9,10]. It has been shown that a number of miRNAs
are expressed in tissue specific manner and contribute in various
biological process like differentiation, immune modulation [11],
fibrosis [12,13] as well as in diseases like cancer [14,15], neuro-
degeneration [16] etc. Recently, miRNA has been implicated
various cardiovascular development, complications and disease
[17,18,19,20,21]. In response to physiological stimuli or patho-
logical condition, such as hypertension, ischemic myocardial
injury, the myocardium reacts with rapid alteration in the gene
expression profile. This adaptation usually results in cardiac
remodeling, which is characterized by severe structural changes of
myocardial tissue, modification of the extracellular matrix, and
reshaping of left ventricle geometry and performance. However,
this process is only an initial ‘‘adaptive’’ response, which leads to
development of long term damage and cardiac dysfunction.
Recently, several reports have revealed important roles of
miRNAs in cardiac hypertrophic growth and heart failure. We
here describe for the first time miRNA expression profiling of
ischemic rat hearts in the context of pre-treatments with pure
resveratrol and a commercially available resveratrol formulation,
longevinex, using quantitative real-time PCR based array.
Furthermore, we have searched for the functional target of the
key miRNA using computational analyses.
Results and Discussion
Resveratrol and longevinex improve cardiac function and
reduce myocardial infarct size and cardiomyocyte
apoptosis in the IR rat heart
In accordance with previous studies [22], both resveratrol and
longevinex improved cardiac output function including aortic flow,
coronary flow, left ventricular developed pressure (LVDP) and its
firstderivativeLVmaxdp/dtina2 hourofreperfusionperiod(Fig.1).
These compounds also lowered the infarct size and death due to
cardiomyocyte apoptosis, as expected. A significant number of
studies exist in the literature demonstrating cardioprotective role of
resveratrol. Recent studies also showed that commercially available
resveratrol formulation longevinex was equally cardioprotective.
We compared the effects of resveratrol with longevinex, because
recent studies determined longevinex to be equally cardioprotective
without exhibiting hormetic action of resveratrol [23]. The
cardioprotective effects of resveratrol and longevinex were consis-
tent with the previously published reports [23].
Global miRNA expression profiling in ischemia-
reperfused rat heart
MicroRNA profiles were analyzed by TLDA array specific for
586 miRNA and five endogeneous control for rat. Array were
carried out in six different groups namely basal level (BL): (1)
Vehicle, (2) Resveratrol, (3) Longevinex, and ischemic repurfused
(IR): (4) Vehicle I/R, (5) pretreated (21days) with Resveratrol I/R
and (5) pretreated (21days) with Longevinex I/R. RNAs were
isolated after 30 min ischemia and 2 hour repurfusion of the heart
from IR samples or from baseline (BL) samples processed the same
way without ischemia and repurfusion. Box Whisker plot
demonstrated unique distribution of total miRNA expression for
all samples. The plot shows the median in the middle of the box,
the 25th percentile (the lower quartile) and the 75th percentile (the
upper quartile) (Fig. 2A). The whiskers are extensions of the box,
snapped to the point within 1.5 times the interquartile. The points
outside the whiskers were plotted and considered as the outliers.
Few miRNAs were observed to be outliers and 385 miRNAs out of
Figure 2. Effects of resveratrol and longevinex on global
miRNA expression. (A) Box-Whisker Plot of miRNA array where
outliers were shown outside the black bar and excluded for analysis.
The data (Ct values) were normalized based on endogeneous genes. (B)
Profile plot of miRNA array filtered on expression (20.0–100.0)th
Percentile in the raw data which were normalized based on
endogeneous genes. BL: Baseline; I/R2h: Ischemia for 30 min and 2 h
reperfusion; VEH: Vehicle, RESV: Resveratrol; LONG: Longevinex.
doi:10.1371/journal.pone.0015705.g002
Figure 1. Effects of resveratrol and longevinex on blood flow, LVDP, dp/dtmax, infarct size and apoptosis. (A) Coronary flow, aortic flow
and LVDP were estimated at baseline and at the indicated times of reperfusion. Infarct size and apoptosis were measured at the end of two hours of
reperfusion. Results are expressed as Means6SEM of six animals per group. *p,0.05 vs. Vehicle (VEH). # p,0.05 vs corresponding I/R. BL: Baseline; I/
R1h: Ischemia for 30 min and 1 h reperfusion; I/R2h: Ischemia for 30 min and 2 h reperfusion; RESV: Resveratrol; LONG: Longevinex.
doi:10.1371/journal.pone.0015705.g001
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conditions. Expressions of 385 miRNAs were shown by profile plot
after normalization to endogeneous control for each samples
(Fig. 2B). miRNA expression were further analyzed by transform-
ing to ‘‘fold change’’ compared to basal level control sample.
Expressions of 213 miRNAs were expressed at least 2 fold or
higher under one of six conditions. The list was further filtered
after looking into miRNA which were either up or down 2-fold in
IR samples. Top 25 miRNAs were listed, which were either up or
down regulated in IR condition (Table 1) and the most regulations
were reversed by pretreatment with resveratrol and longevinex. IR
samples pretreated with resveratrol and longevinex both reversed
the up or down regulation in IR Control in the opposite direction
in 11 of the 25 miRNAs listed in Table 1. Either resveratrol or
longevinex, but not both, reversed the up or down regulation
compared to IR control in 5 instances. In rest of 9 miRNAs
expression were attenuated by either or both. Longevinex
exceeded the effect of resveratrol in 15 of the 25 miRNAs
including miR-10a, miR-20b, miR-21. However, in few miRNAs
such as miR-29c, longevinex have opposing effect to resveratrol
and the difference may be due to many possibilities including
presence of other ingredients in commercial formulation, bio-
availability of resveratrol etc. There was a tremendous upregula-
tion of miR-21 expression in basal level controls with resveratrol
(up 391.4) and longevinex (760.9) which was lowered considerably
in IR (up 61.5 and 59.3). miR-539 is upregulated to high level (214
fold) in IR samples and were further up-regulated in resveratrol
preteated samples. Similar observation were also found in miR-
27a, miR-101, miR-9, miR-667. Similar but less pronounced
change were also found in many other miRNAs. Selected miRNAs
were also shown in the scatter plot (Fig. 3A), where double lines
indicated as fold change of 2.
miR-539, the highest upregulated miRNA have 271 conserved
gene target however functional target has not been reported in the
literature. The targets of miR-539 obtained by computational
analyses include matrix metallopeptidase 20, fibroblast growth
factor 14, clathrin, light polypeptide, osteoprotegerin and
transcription factors like forkhead box B1, which may have roles
in cardiac remodeling. miR-21 were shown to regulate the ERK-
MAP kinase signalling pathway in cardiac fibroblasts, which has
role on global cardiac structure and function [24]. It has been also
shown earlier that resveratrol triggers MAPK signaling pathway as
a preconditioning mechanism in heart [25]. We also looked in
samples the ERK-MAPK pathway. ERK phosphorylation was
observed to be increased in both resveratrol and longevinex
treated baseline samples and reduced in corresponding IR samples
(Fig. 4A). Similar but opposing effect observed in p38 phosphor-
ylation where significantly less phosphorylation occurred in
resveratrol or longevinex treated BL samples. Increased p38
MAPK phosphorylation occurred in I/R2h samples and attenu-
ated in both resveratrol and longevinex treated I/R2h samples due
to preconditioning (Fig. 4B). VEGF is modulated by miR-20b
Table 1. Differential expression of microRNA expressed in fold change with respect to basal level control heart sample.
miRNA BL Resveratrol BL Longevinex IR Control IR Resveratrol IR Longevinex
miR-539 up 1272.9 up 642.7 up 214.3 up 172.4 up 314.6
miR-27a up 2.2 up 2.1 up 9.3 up 5.5 up 1.4
miR-101a up 28.4 up 39.2 up 6.1 up 3.1 up 3.3
miR-9 up 2.6 up 1.1 up 5.4 down 1.7 down 1.1
miR-667 up 8.2 up 6.3 up 4.4 up 2 up 1.2
miR-339-5p up 13.6 up 20.7 up 4.1 down 1.4 down 3.8
rno-miR-345-3p up 40.8 up 23.1 up 3.7 down 12 down 1.1
miR-10a up 6.4 up 5.2 up 3.5 down 116 down 1.6
snoRNA202 up 3.8 up 4.7 up 3.2 down 6 down 3
miR-27b down 1.4 up 1.9 up 3.2 up 1 up 1
miR-29c up 5.4 up 4.5 up 3.1 up 1.5 down 1.5
miR-345-5p up 14.3 up 31.7 up 2.4 down 4.7 up 1.1
rno-miR-24-1 down 25.3 up 1.2 up 2.1 down 1.2 down 1.9
miR-687 up 3.8 up 1.8 up 2 down 1.7 down 11.5
miR-27a up 34 up 12.8 up 1.6 down 1.7 up 1.5
miR-31 up 2.4 up 1.1 up 1.6 down 17.5 down 2.1
miR-20b down 6 down 38.8 down 112.9 down 189 down 1366
miR-760 down 2.7 up 2.5 down 30.8 up 1.5 up 2.2
miR-351 up 3.9 up 9.1 down 20.9 down 1.3 up 1.9
miR-181c up 5.3 up 4.2 down 6.7 up 1.4 down 9.1
miR-21 up 391.4 up 760.9 down 4 up 61.5 up 59.3
miR-25 up 25 up 11.5 down 1.9 up 1.1 up 4.2
rno-miR-450a up 4.8 up 2.4 down 1.7 down 1.5 down 5.4
miR-214 up 4.2 up 6.2 down 1.3 down 3.9 down 6.5
miR-324-3p up 4.9 up 6.5 down 1.2 down 5.6 down 5.3
Top 25 miRNA were listed based its up or down regulation in IR samples.
doi:10.1371/journal.pone.0015705.t001
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miR-27a in cancer cells [26,27]. SIRT1 were observed to be
regulated by miR-9 in stem cells [28]. Recent studies demonstrat-
ed the increase of miR-1 in coronary artery diseases (CAD) and
miR-1 is downregulated by beta-blocker propranolol in rat model
of myocardial infarction [29]. Specific modulations of microRNA
by resveratrol have not shown in any in vivo models. Recently
microarray analysis of the effect of resveratrol has been
demonstrated in human acute monocytic leukemia cell line
(THP-1) and human colon adenocarcinoma cell line (SW480)
[30,31]. Resveratrol decreases the levels of miR-155 in THP-1 and
modulating JunB and JunD, key regulators in carcinogenesis [31].
Resveratrol also modulates microRNA targeting effectors of
TGFbeta pathways [30]. Treatment with resveratrol in cancer
cell line SW480 results in decreased level of miR-21 and miR29c
whereas it was increased in healthy heart when treated with
resveratrol. This anomaly may be due to the fact that
cardiomyocytes is barely dividing cells whereas SW480 cells grow
rapidly which leads to complete different microenvironment inside
cells. It is also important to point out that the doses for resveratrol
is much higher (50micromolar) in cancer cells and similar dose is
partially detrimental to human cardiomyocytes and endothelial
cells in cultures (data not shown). Birds-eye-view of overall
mapping of expression values were depicted by heatmap, a
color-bar created by the range of values in the conditions of the
interpretation (Fig. 3B). The expression value of each gene is
mapped to a color-intensity value. It is evident from heat map that
treatment with either resveratrol or longevinex in control samples
altered significant miRNA expression levels, some of them may
play significant key roles in cardio-protection.
IR hearts pre-treated with resveratrol and longevinex
closely related to miRNA pattern of BL control
Principal component analyses of the six samples revealed that
the samples IR longevinex and IR resveratrol were remarkably
Figure 3. Effects of resveratrol and longevinex on miRNA expression pattern. (A) Correlation of miRNA expressions between basal level
and IR control heart using scatter plot: Few miRNA expressions were selected for display as shown in table 1. (B) Heatmap for cluster analyses of
differentially expressed miRNA among samples: Each miRNA was represented as single bar based from their Ct values and color coding was shown
below with a gradient from blue (negative and lowest Ct values) to red (positive and highest Ct values). miRNAs not detected were shown as black
bars. Each column was represented sample indicated on top. (C) Principal component analyses of all samples. This multivariate analysis demonstrated
the proximity of longivinex and resveratrol treated IR samples to the control (vehicle) samples. BL: Baseline; IR: Ischemia for 30 min and 2 h
reperfusion; VEH: Vehicle, RESV: Resveratrol; LONG: Longevinex.
doi:10.1371/journal.pone.0015705.g003
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In the majority of cases, they also were readily distinguished from
each group. These results are indeed of utmost importance, as they
document that both resveratrol and longevinex can protect the
ischemic heart by restoring the IR-induced up-regulation or down-
regulation of gene expression.
Integrative analyses of miRNA for target gene and
pathway analyses
Differentially expressed miRNAs were further analyzed for their
putativetargetgenesusingTargetScanandwerelistedinthetable2.
Most of the target genes(.1400 genes) have molecular function of
metal ion binding, calcium-potassium-chloride ion binding, corre-
lated to the restructuring heart after IR damage. Importantly,
miRNA target gene modulated sequence specific DNA factor such
as FOXO1, TRAF3 etc. SirT1 regulates several transcription
factors including FoxO1, which is inactivated by phosphorylation
via Akt [32]. Recent publication showed the phosphorylation of
FoxO1 along with the activation of SirT1, SirT3 and SirT4 are
localized in mitochondria where they regulate aging and energy
metabolism.[4] Over the years,SIRT1wasknown tobe activated by
resveratrol [33]. However, resveratrol may have no direct roles in
activating SIRT1 [34]. Since dysregulation of miRNAs such as
miR-21 is directly linked with cardiac diseases like ischemic heart
disease and since resveratrol can ameliorate myocardial ischemic
reperfusion injury through the modulation of several miRNAs, the
results of the present study explains the mechanism of complex
regulatory network mediated by resveratrol through miRNA in
cardioprotection.
In summary, microRNA regulate target gene mostly by
translational repression and sometimes through translational
activation. Here, we demonstrated that resveratrol or longevinex
regulated miRNA expression in healthy heart and ischemic-
repurfused heart. Future detailed studies based on these analyses
will pave the way for development of novel therapeutic
intervention for cardioprotection in actute I/R injury.
Methods
Animals
All animals used in this study received humane care in
compliance with the regulations relating to animals and experi-
ments involving animals and adheres to principles stated in the
Guide for the Care and Use of Laboratory Animals, NIH
Publication, 1996 edition, and all the protocols (Proposal # 2008-
484) were approved by the Institutional Animal Care Committee
of University of Connecticut Health Center, Farmington, CT,
USA. Male Sprague–Dawley rats weighing between 250 and
300 g were fed ad libitum regular rat chow with free access to
water until the start of the experimental procedure. Animals were
gavaged with either resveratrol (5 mg/kg/day) [Sigma Chemical
Company, St. Louis, MO] or longevinex (100 mg/kg/day)
[Longevinex Inc, North Las Vegas, NV] for 21 days. Previous
studies from our laboratory established the appropriate dose and
time periods for each compound used in this experiment [35,36].
Isolated working heart preparation and assessment of
cardiac function
After completing the feeding protocol, the animals were
anesthetized with sodium pentobarbital (80 mg/kg, i.p.) (Abbott
Laboratories, North Chicago, IL, USA), and intraperitonealy
heparin sodium (500 IU/kg, i.v.) (Elkins-Sinn Inc., Cherry Hill,
NJ, USA) was used as an anticoagulant. After the deep anesthesia
was conformed, hearts were excised, the aorta was canulated, and
the hearts were perfused through the aorta in Langendorff mode
at a constant (100 cm of water) perfusion pressure at 37uC with the
KHB for a 5 min washout period as described previously. The
perfusion medium consisted of a modified Krebs-Henseleit
bicarbonate buffer (millimolar concentration: sodium chloride
118, potassium chloride 4.7, calcium chloride 1.7, sodium
bicarbonate 25, potassium dihydrogen phosphate 0.36, magne-
sium sulfate 1.2 and glucose 10), and after its oxygenization pH
was 7.4 at 37uC. During the washout period left atria was
canulated, and the Langendorff preparation was switched to the
working mode for 10 min with a left atrial 6 filling pressure of
17 cm H2O, aortic afterload pressure was set to 100 cm of water.
At the end of 10 min, baseline cardiac function like heart rate
(HR, beats/min), aortic flow (AF, ml/min), coronary flow (CF,
ml/min), left ventricular developed pressure (LVDP, mmHg) and
first derivative of developed pressure (LVdp/dt, mmHg/sec) were
recorded. After that 30 min of global ischemia was initiated by
clamping the left atrial inflow and aortic outflow lines at a point
close to their origins. At the end of the 30 min of ischemia,
reperfusion was initiated for 60 min or 120 min by unclamping
Figure 4. Effects of resveratrol and longevinex on phosphor-
ylation of ERK1/2 and p38 MAPK. (A) Ratio of ERK1/2 phosphor-
ylation to total ERK1/2 were plotted in samples as indicated. (B) Ratio of
p38 MAPK phosphorylation to total p38 MAPK were plotted in samples
as described. Results are expressed as Means6SEM of six animals per
group. *p,0.05 vs. Vehicle (VEH). # p,0.05 vs corresponding I/R. BL:
Baseline; I/R2h: Ischemia for 30 min and 2 h reperfusion; RESV:
Resveratrol; LONG: Longevinex.
doi:10.1371/journal.pone.0015705.g004
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reperfusion was in Langendorff mode to avoid the ventricular
fibrillations, after the hearts were switched to anterograde working
mode [4].
Infarct size estimation
Infarct size was measured according to the TTC method [4,7].
After the 2 h of reperfusion, 40 ml of 1% (w/v) solution of
triphenyl tetrazolium chloride (TTC) in phosphate buffer was
infused into aortic cannula, and the heart samples were stored at -
70uC for subsequent analysis. Sections (0.8 mm) of frozen heart
were fixed in 2% paraformaldehyde, placed between two cover
slips and digitally imaged using a Microtek ScanMaker 600z. To
quantitate the areas of infarct in pixels, standard NIH image
program was used. The infarct size was quantified and expressed
in pixels [4,7].
Assessment of apoptotic cell death
Immunohistochemicaldetectionofapoptoticcellswascarried out
using the TUNEL method [4,7] (Promega, Madison, WI). Briefly,
after the isolated heart experiments the heart tissues were
immediately put in 10% formalin and fixed in an automatic tissue
fixing machine. The TUNEL staining was performed according to
the manufacturer’s instructions. The fluorescence staining was
viewed with a fluorescence microscope (AXIOPLAN2 IMAGING,
Carl Zeiss Microimaging Inc., New York) at 520620 nm for green
fluorescence of fluorescein and at 620 nm for red fluorescence of
propidium iodide. The number of apoptotic cells was counted and
expressed as a percent of total myocyte population.
Micro RNA isolation and cDNA preparation
Total RNA from rat heart samples were isolated using Trizol
reagent (Invitrogen) and further purified using mirVANA miRNA
isolation kit (Ambion) [37]. cDNAs were prepared using Taqman
miRNA Reverse Transcription kit and Megaplex Rodent Pool A
and B primers sets.
Profiling of miRNA expression
miRNA expression profiling were carried out using quantitative
real-time PCR method by TaqManH Gene Signature Rodent
Arrays on a 384 well micro fluidic card in 7900HT Realtime PCR
machine(Applied Biosystem, Foster City) according to manufac-
turer’s recommendation. Each miRNA were quantified by two
specific amplicon primers and one specific probe. Comprehensive
coverage of Sanger miRBase v10 was enabled across a two-card
set of TaqManH MicroRNA Low Density Arrays (TLDA Array A
and B) for a total of 518, and 303 unique assays, specific to rat
miRNAs, respectively. In addition, each array contains six control
assays—five carefully selected candidate endogenous control
assays, and one negative control assay. Profiling of miRNA by
array has been used previously [38].
Analyses of miRNA gene expression data
Realtime PCR data expressed as Ct values from array A and B
were combined using R script (provided by GeneSpring
Informatics Support Team) and processed using GeneSpringGX
11.0.2 software (Agilent Technologies, Santa Clara). After analysis
591 entities were detected from array A and B. All statistical
analyses including normalization to endogeneous control, quality
control, filtering, correlation analyses and principal component
analyses were carried out by GeneSpring GX software.
miRNA Target prediction
miRNA targets have been predicted using TargetScan in-built
and plugged within GeneSpring GX software.
Western Blot analysis
Hearts were homogenized in a buffer containing 25 mM Tris-
HCl, 25 mM NaCl, 1 mM orthovanadate, 10 mM NaF, 10 mM
pyrophosphate, 10 mM okadaic acid, 0.5 mM EDTA, and 1 mM
phenylmethylsulfonyl fluoride. One hundred micrograms protein
of each heart homogenates separated by SDS-polyacrylamide gel
electrophoresis and immobilized on polyvinylidene difluoride
membrane. The membrane was immune-blotted with ERK1/2,
phospho-ERK1/2, p38 MAPK and phospho-p38 MAPK (Cell
signaling Technology, MA) to evaluate the phosphorylation of the
compounds. The resulting blots were digitized and subjected to
densitometric scanning using a standard NIH image program.
Statistical analysis
The values for myocardial function parameters, infarct size and
apoptosis were expressed as the mean 6 standard error of mean
(SEM). A one-way analysis of variance was first carried out to test
for any differences in mean values between groups. If differences
were established, the values of the resveratrol-treated groups were
compared with those of the control group by modified t-test. The
results were considered significant if p,0.05.
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